Drugs / Interferon beta type 1a
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03958877 Comparator | Oct 2019 → May 2027 expected | relapsing-remitting multiple sclerosis | Biogen | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon beta type 1a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03958877 ↗ |
| Known as | Avonex | “Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1” NCT03958877 ↗ |
| Route | Intramuscular | “30 μg intramuscular (IM) injections every week” NCT03958877 ↗ |